MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - indian pharma
- SUN PHARMA - TTK HEALTHCARE
SUN PHARMA vs TTK HEALTHCARE - Comparison Results
Current Valuations
| SUN PHARMA | TTK HEALTHCARE | SUN PHARMA/ TTK HEALTHCARE |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 18.7 | 15.1 | 123.7% | View Chart |
| P/BV | x | 2.0 | 1.0 | 196.8% | View Chart |
| Dividend Yield | % | 0.8 | 1.5 | 52.6% |
Financials
 SUN PHARMA  TTK HEALTHCARE |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| SUN PHARMA Mar-19 |
TTK HEALTHCARE Mar-19 |
SUN PHARMA/ TTK HEALTHCARE |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 679 | 1,215 | 55.9% | |
| Low | Rs | 375 | 610 | 61.5% | |
| Sales per share (Unadj.) | Rs | 121.1 | 444.4 | 27.3% | |
| Earnings per share (Unadj.) | Rs | 13.4 | 17.2 | 77.6% | |
| Cash flow per share (Unadj.) | Rs | 20.7 | 27.6 | 74.9% | |
| Dividends per share (Unadj.) | Rs | 2.75 | 5.00 | 55.0% | |
| Dividend yield (eoy) | % | 0.5 | 0.5 | 95.2% | |
| Book value per share (Unadj.) | Rs | 172.6 | 177.9 | 97.0% | |
| Shares outstanding (eoy) | m | 2,399.26 | 14.13 | 16,979.9% | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 4.4 | 2.1 | 211.9% | |
| Avg P/E ratio | x | 39.4 | 52.9 | 74.5% | |
| P/CF ratio (eoy) | x | 25.5 | 33.0 | 77.2% | |
| Price / Book Value ratio | x | 3.1 | 5.1 | 59.6% | |
| Dividend payout | % | 20.6 | 29.0 | 70.9% | |
| Avg Mkt Cap | Rs m | 1,264,650 | 12,894 | 9,807.8% | |
| No. of employees | `000 | 17.5 | 2.3 | 757.0% | |
| Total wages/salary | Rs m | 59,671 | 1,307 | 4,565.5% | |
| Avg. sales/employee | Rs Th | 16,608.1 | 2,715.7 | 611.6% | |
| Avg. wages/employee | Rs Th | 3,409.6 | 565.3 | 603.1% | |
| Avg. net profit/employee | Rs Th | 1,833.8 | 105.4 | 1,739.7% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 290,659 | 6,279 | 4,629.2% | |
| Other income | Rs m | 10,255 | 78 | 13,232.1% | |
| Total revenues | Rs m | 300,914 | 6,356 | 4,734.1% | |
| Gross profit | Rs m | 63,076 | 496 | 12,727.2% | |
| Depreciation | Rs m | 17,533 | 147 | 11,951.3% | |
| Interest | Rs m | 5,553 | 34 | 16,427.5% | |
| Profit before tax | Rs m | 50,246 | 393 | 12,798.2% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | -12,144 | 0 | - | |
| Tax | Rs m | 6,009 | 149 | 4,035.5% | |
| Profit after tax | Rs m | 32,093 | 244 | 13,169.1% | |
| Gross profit margin | % | 21.7 | 7.9 | 274.9% | |
| Effective tax rate | % | 12.0 | 37.9 | 31.5% | |
| Net profit margin | % | 11.0 | 3.9 | 284.5% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 310,692 | 2,717 | 11,434.3% | |
| Current liabilities | Rs m | 173,396 | 1,571 | 11,038.7% | |
| Net working cap to sales | % | 47.2 | 18.3 | 258.7% | |
| Current ratio | x | 1.8 | 1.7 | 103.6% | |
| Inventory Days | Days | 99 | 32 | 308.0% | |
| Debtors Days | Days | 112 | 47 | 239.1% | |
| Net fixed assets | Rs m | 232,477 | 991 | 23,458.8% | |
| Share capital | Rs m | 2,399 | 141 | 1,698.0% | |
| "Free" reserves | Rs m | 411,691 | 2,373 | 17,349.1% | |
| Net worth | Rs m | 414,091 | 2,514 | 16,469.4% | |
| Long term debt | Rs m | 15,226 | 3 | 447,826.5% | |
| Total assets | Rs m | 646,938 | 4,158 | 15,558.5% | |
| Interest coverage | x | 10.0 | 12.6 | 79.7% | |
| Debt to equity ratio | x | 0 | 0 | 2,719.1% | |
| Sales to assets ratio | x | 0.4 | 1.5 | 29.8% | |
| Return on assets | % | 5.8 | 6.7 | 87.2% | |
| Return on equity | % | 7.8 | 9.7 | 80.0% | |
| Return on capital | % | 10.2 | 16.9 | 60.0% | |
| Exports to sales | % | 0 | 3.6 | 0.0% | |
| Imports to sales | % | 0 | 0.5 | 0.0% | |
| Exports (fob) | Rs m | NA | 225 | 0.0% | |
| Imports (cif) | Rs m | NA | 31 | 0.0% | |
| Fx inflow | Rs m | 66,025 | 225 | 29,318.6% | |
| Fx outflow | Rs m | 38,610 | 71 | 54,296.4% | |
| Net fx | Rs m | 27,415 | 154 | 17,791.7% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 21,965 | 173 | 12,688.9% | |
| From Investments | Rs m | -6,813 | 97 | -7,059.6% | |
| From Financial Activity | Rs m | -27,305 | -307 | 8,885.5% | |
| Net Cashflow | Rs m | -8,442 | -38 | 22,391.2% | |
Share Holding
| Indian Promoters | % | 63.7 | 65.4 | 97.4% | |
| Foreign collaborators | % | 0.0 | 0.0 | - | |
| Indian inst/Mut Fund | % | 5.1 | 3.7 | 138.6% | |
| FIIs | % | 23.0 | 5.2 | 442.3% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 8.3 | 25.8 | 32.2% | |
| Shareholders | 133,026 | 12,723 | 1,045.6% | ||
| Pledged promoter(s) holding | % | 0.5 | 0.0 | - |
Compare SUN PHARMA With: PIRAMAL ENTERPRISES GSK PHARMA DR. DATSONS LABS DR. REDDYS LAB NOVARTIS
Compare SUN PHARMA With: ACTAVIS (US) MYLAN (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Today's Market
Nifty Below 8,300 Mark, Fiscal Deficit in Feb, Maruti Suzuki Sales, and Top Cues in Focus Today(Pre-Open)
Indian share markets extended losses in the first trading session of FY21 on Wednesday. Losses were seen as the number of coronavirus cases in the country continued to rise.
Related Views on News
SUN PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 29.8% (Quarterly Result Update)
Feb 7, 2020 | Updated on Feb 7, 2020For the quarter ended December 2019, SUN PHARMA has posted a net profit of Rs 10 bn (down 29.8% YoY). Sales on the other hand came in at Rs 82 bn (up 5.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
TTK HEALTHCARE Announces Quarterly Results (3QFY20); Net Profit Down 8.3% (Quarterly Result Update)
Jan 30, 2020 | Updated on Jan 30, 2020For the quarter ended December 2019, TTK HEALTHCARE has posted a net profit of Rs 45 m (down 8.3% YoY). Sales on the other hand came in at Rs 2 bn (up 11.2% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.
SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)
Aug 14, 2019 | Updated on Aug 14, 2019For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
TTK HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 53.8% (Quarterly Result Update)
Aug 13, 2019 | Updated on Aug 13, 2019For the quarter ended June 2019, TTK HEALTHCARE has posted a net profit of Rs 36 m (down 53.8% YoY). Sales on the other hand came in at Rs 2 bn (up 3.2% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.
SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)
Aug 6, 2019 | Updated on Aug 6, 2019Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.
More Views on NewsMost Popular
Sorry Warren Buffett, I'm Following This Man Instead of You in 2020(The 5 Minute Wrapup)
Mar 30, 2020This man warned of an impending market correction while everyone else was celebrating the renewed optimism in early 2020...
A Big Trading Opportunity is Coming Your Way Soon(Fast Profits Daily)
Mar 25, 2020I see a big opportunity to make fast profits on the horizon.
The Biggest Trading Opportunity of 2020 is Here...
Mar 26, 2020India's #1 trader, Vijay Bhambwani, talks about a hugely profitable trading opportunity which you must know about today!
Coronavirus Sell-off Is a Perfect Time to 'Lockdown' this 'Crorepati' Stock(Profit Hunter)
Mar 24, 2020Coronavirus crisis and panic selling has brought this quality smallcap to multiyear lows, making it a great bargain.
Lockdown! Now the Bailout...(The Honest Truth)
Mar 25, 2020Ajit Dayal on what India should do to manage the coronavirus impact on the economy.
MoreOUR TOP 5 IDEAS
- How to Trade the Coronavirus Crash - Download this FREE Report Now
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- A Guide to some of the Most Lucrative Stocks in the Market. Download For Free!
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- Find Out Our Top 7 Bluechips for 2020 Virtually FREE. Click Here Now!
SUN PHARMA SHARE PRICE
Apr 1, 2020 (Close)
TRACK SUN PHARMA
- Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON SUN PHARMA
SUN PHARMA 5-YR ANALYSIS
COMPARE SUN PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.